Figure 1From: Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma5T4-specific T cell responses in patients with (A) progressive disease and (B) stable disease.Back to article page